ES2163389T3 - Uso de 5-metil-1-fenil-2-(1h)-piridona en la prevencion de lesiones fibroticas. - Google Patents

Uso de 5-metil-1-fenil-2-(1h)-piridona en la prevencion de lesiones fibroticas.

Info

Publication number
ES2163389T3
ES2163389T3 ES90301607T ES90301607T ES2163389T3 ES 2163389 T3 ES2163389 T3 ES 2163389T3 ES 90301607 T ES90301607 T ES 90301607T ES 90301607 T ES90301607 T ES 90301607T ES 2163389 T3 ES2163389 T3 ES 2163389T3
Authority
ES
Spain
Prior art keywords
methyl
fibrotic
phenyl
prevention
piridone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90301607T
Other languages
English (en)
Inventor
Solmon B Margolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2163389T3 publication Critical patent/ES2163389T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LAS COMPOSICIONES COMPRENDIENDO 5-METILO-1-FENILO-2-(1H)PIRIDONA SON EFECTIVAS PARA LA REPARACION Y PREVENCION DE LESIONES FIBROTICAS COMO LA ASBESTOSIS. LA 5-METILO-1-FENILO2-(1H)-PIRIDONA EJERCE SOBRE LA ANTI-FIBROSIS UNA ACTIVIDAD TOTALMENTE DIFERENTE A, E INDEPENDIENTE DE, LA ACTIVIDAD FIBRINOLITICA.
ES90301607T 1989-02-15 1990-02-15 Uso de 5-metil-1-fenil-2-(1h)-piridona en la prevencion de lesiones fibroticas. Expired - Lifetime ES2163389T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1035436A JPH02215719A (ja) 1989-02-15 1989-02-15 線維化病変組織の修復並びに線維化病変の阻止剤

Publications (1)

Publication Number Publication Date
ES2163389T3 true ES2163389T3 (es) 2002-02-01

Family

ID=12441800

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01107235T Expired - Lifetime ES2220612T3 (es) 1989-02-15 1990-02-15 Composicion que contiene 5-metil-1-fenil-2-(1h)-piridona para reparar y prevenir lesiones fibroticas.
ES90301607T Expired - Lifetime ES2163389T3 (es) 1989-02-15 1990-02-15 Uso de 5-metil-1-fenil-2-(1h)-piridona en la prevencion de lesiones fibroticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01107235T Expired - Lifetime ES2220612T3 (es) 1989-02-15 1990-02-15 Composicion que contiene 5-metil-1-fenil-2-(1h)-piridona para reparar y prevenir lesiones fibroticas.

Country Status (9)

Country Link
EP (3) EP0458861B1 (es)
JP (1) JPH02215719A (es)
AT (1) ATE136215T1 (es)
AU (1) AU633541B2 (es)
CA (1) CA2010017C (es)
DE (2) DE69034143T2 (es)
DK (1) DK0458861T3 (es)
ES (2) ES2220612T3 (es)
WO (1) WO1990009176A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
CA2161648A1 (en) * 1993-05-07 1994-11-24 Solomon B. Margolin Compositions and methods for reparation and prevention of fibrotic lesions
BR9607541A (pt) * 1995-03-03 1997-12-23 Solomon Begelfor Margolin Tratamento de doenças que tem por causa o fator de crescimento da citoquina
US6492395B1 (en) 1998-09-18 2002-12-10 Mepha Ag Topical formulation of alkyl-, phenyl-pyridone
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP4542743B2 (ja) 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
TW200501952A (en) * 2003-02-21 2005-01-16 Shionogi & Co Pirfenidone gel formulations
TW200418516A (en) * 2003-02-21 2004-10-01 Shionogi & Co Droplet dispersed ointment
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007147297A1 (fr) 2006-06-15 2007-12-27 Shanghai Genomics, Inc. Utilisation de dérivés de pyridone destinés à prévenir et traiter par radioactivité une lésion des poumons
MX2007006347A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo uso de 5-metil-1-fenil-2-(1h)-piridona para el tratamiento y prevencion de cicatrices hipertroficas, y composicion conteniendo la misma.
CA2691379C (en) 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
WO2010045871A1 (en) * 2008-10-21 2010-04-29 Dieretech Investment Limited Composition and method for treating proteinuria
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
ES2913095T3 (es) * 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
CN103561741A (zh) 2011-03-08 2014-02-05 奥斯拜客斯制药有限公司 取代的n-芳基吡啶酮
KR102045723B1 (ko) * 2011-09-14 2019-11-18 시오노기 앤드 컴파니, 리미티드 흡입용 의약 조성물
ES2716008T3 (es) 2012-07-18 2019-06-07 Sunshine Lake Pharma Co Ltd Derivados heterocíclicos nitrogenados y su aplicación en fármacos
US12226407B2 (en) 2012-07-24 2025-02-18 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
US9902712B2 (en) * 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
EP3307714A1 (en) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
MX2020005775A (es) * 2020-07-13 2022-01-14 Centro De Retina Medica Y Quirurgica S C Uso farmaceutico de pirfenidona para la reduccion de fibrosis cardiaca en pacientes con cardiomiopatia y/o esteatosis cardiaca y/o covid-19.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6816241A (es) * 1967-12-01 1969-06-03
US3721676A (en) * 1969-11-12 1973-03-20 Merck & Co Inc Certain 3-amino-2(1h)pyridones
US3644626A (en) * 1969-11-25 1972-02-22 Merck & Co Inc Novel pyridones in compositions and methods for treating inflammation pain and fever
US3655897A (en) * 1971-01-25 1972-04-11 Merck & Co Inc Anti-inflammatory agents
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
CA1049411A (en) * 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
ZA757570B (en) * 1974-12-09 1977-07-27 Affiliated Med Res A useful n-substituted pyridone
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤

Also Published As

Publication number Publication date
EP0383591A2 (en) 1990-08-22
AU633541B2 (en) 1993-02-04
DE69034143T2 (de) 2005-06-30
DE69033863T2 (de) 2002-06-13
ES2220612T3 (es) 2004-12-16
DK0458861T3 (da) 1996-08-12
AU4981290A (en) 1990-08-23
EP0458861A4 (en) 1992-07-08
EP1138329A3 (en) 2002-04-17
EP0383591A3 (en) 1992-01-15
JPH0552814B2 (es) 1993-08-06
EP1138329B1 (en) 2004-06-02
ATE136215T1 (de) 1996-04-15
EP1138329B8 (en) 2006-05-17
CA2010017A1 (en) 1990-08-15
WO1990009176A1 (en) 1990-08-23
EP0458861B1 (en) 1996-04-03
CA2010017C (en) 1995-09-05
EP1138329A2 (en) 2001-10-04
JPH02215719A (ja) 1990-08-28
DE69034143D1 (de) 2004-07-08
EP0458861A1 (en) 1991-12-04
DE69033863D1 (de) 2002-01-03
EP0383591B1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
AU4981290A (en) Composition for reparation and prevention of fibrotic lesions
DK0435436T3 (da) Transdermale fluxfremmere i kombination med iontoforese ved topisk administrering af farmaceutiske præparater
FI19992420L (fi) Mikrobifytaasin kloonaus ja ilmentäminen
DE69118526D1 (de) Mittel zur transdermalen penetration von arzneimitteln
BR8700699A (pt) Composicao de protecao de madeira
BR8907066A (pt) Corpo rolante
FI862689A7 (fi) Hapetusta kestävä kudos kuivapesussa käytettäviä aktiivisia aineita varten ja valkaisua kestäviä tuotteita.
IT8022185A0 (it) Strumento per la cura dei piedi di notevole versatilita' di uso.
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
FI911269A7 (fi) Menetelmä ja koostumus aktiivisten aineiden lisääntyneen pitoisuuden aikaansaamiseksi iholla iontoforeesin avulla
AU6820087A (en) Amine oxide and use as surfactant in detergent compositions
DK0429982T3 (da) Sammensætninger med kontrolleret slip samt anvendelse
ES2045008T3 (es) Procedimiento para la obtencion de preparados en combinacion antidepresivos.
ATA44587A (de) Fahrbare gleisbearbeitungsmaschine fuer den weichen- und kreuzungsbereich
DK100087D0 (da) Transdermale 3-phenoxypyridin-praeparater
ES292519Y (es) Nudo estructural para conformacion de entreplantas en almacenes y similares
BR6401935U (pt) Carrinho de chopp ambulantes
PT83547A (pt) Mesa de trabalho com prancha de trabalho e armacao
IT8847888A0 (it) Composizioni erbicide sinergiche erelativo impiego di applicazione
ES279005Y (es) Dispositivo perfeccionado limpiador, fregador y abrillantador
ES1002763Y (es) Adaptador porta-accesorios para mesas y muebles similares
ATA61587A (de) Hoehenverstellbares tischgestell fuer arbeits- und werktische
BR9500352A (pt) Sistema de utilizaçao de troca de pallets (mesas) e utilização simultânea dos pallets (mesas) em máquinas ferramenta
IT9020835A1 (it) Utensile perfezionato per tagliare e servire porzioni di pizza e simili
BR8700264A (pt) Maquina para obtencao de peca de madeira aplicada em vassouras ou similares

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 383591

Country of ref document: ES